Corcept (NASDAQ: CORT) director sells 10,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) director James N. Wilson reported indirect sales of common stock on August 14, 2026 by the James N. Wilson and Pamela D. Wilson Trust. The trust sold a total of 10,000 shares in multiple open-market transactions at weighted average prices between about $110 and $113 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. Wilson has voting power over the trust’s shares but disclaims beneficial ownership except to the extent of his pecuniary interest. Separate indirect holdings entries report 200,000 shares of common stock in each of the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 5 txns

Insider WILSON JAMES N

Role Director

Sold 10,000 shs ($1.11M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F5	3,053	$110.4949	$337K
Sale	Common Stock F1, F3, F5	4,668	$111.4425	$520K
Sale	Common Stock F1, F4, F5	2,279	$112.6398	$257K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,074,543 shares (Indirect, James N. Wilson and Pamela D. Wilson Trust); Common Stock — 200,000 shares (Indirect, James N. Wilson 2025 Grantor Retained Annuity Trust); Common Stock — 200,000 shares (Indirect, Pamela D. Wilson 2025 Grantor Retained Annuity Trust)

Footnotes (5)

1. F1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.
2. F2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.00 to $110.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.01 to $112.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.51 to $112.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. F5. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Key Figures

Shares sold (tranche 1): 3,053 shares Price range tranche 1: $110.00–$110.98 per share Shares sold (tranche 2): 4,668 shares +5 more

8 metrics

Shares sold (tranche 1) 3,053 shares Indirect sale on August 14, 2026 at $110.4949 weighted average price

Price range tranche 1 $110.00–$110.98 per share Actual sale price range for 3,053-share tranche

Shares sold (tranche 2) 4,668 shares Indirect sale on August 14, 2026 at $111.4425 weighted average price

Price range tranche 2 $111.01–$112.00 per share Actual sale price range for 4,668-share tranche

Shares sold (tranche 3) 2,279 shares Indirect sale on August 14, 2026 at $112.6398 weighted average price

Price range tranche 3 $112.51–$112.83 per share Actual sale price range for 2,279-share tranche

Total shares sold 10,000 shares Aggregate indirect open-market sales on August 14, 2026

GRAT holdings 200,000 shares Indirect holdings in each of the 2025 Grantor Retained Annuity Trusts as of August 14, 2026

Key Terms

Rule 10b5-1 plan, Grantor Retained Annuity Trust, weighted average sale price, pecuniary interest

4 terms

Rule 10b5-1 plan regulatory

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Grantor Retained Annuity Trust financial

"James N. Wilson 2025 Grantor Retained Annuity Trust"

A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold"

pecuniary interest financial

"disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest"

FAQ

What insider transactions did CORT director James N. Wilson report on August 14, 2026?

James N. Wilson reported indirect sales of 10,000 shares of Corcept Therapeutics (CORT) common stock on August 14, 2026, executed in multiple open-market transactions by the James N. Wilson and Pamela D. Wilson Trust.

At what prices were the 10,000 CORT shares sold by the Wilson trust?

The 10,000 CORT shares were sold at weighted average prices around $110.49, $111.44, and $112.64 per share, with actual sale prices ranging from $110.00 to $112.83 per share.

Were James N. Wilson’s August 14, 2026 CORT stock sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 12, 2026 and in effect at the time of the sales.

How are the sold CORT shares held in relation to James N. Wilson?

The 10,000 CORT shares sold were held indirectly through the James N. Wilson and Pamela D. Wilson Trust. Wilson has voting power over these shares but disclaims beneficial ownership except to the extent of his pecuniary interest.

What ongoing indirect CORT holdings are disclosed for the Wilson GRATs?

The filing lists indirect holdings of 200,000 CORT shares in the James N. Wilson 2025 Grantor Retained Annuity Trust and 200,000 CORT shares in the Pamela D. Wilson 2025 Grantor Retained Annuity Trust as of August 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 04:31 PM Accepted by SEC EDGAR 08/18/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WILSON JAMES N

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		S(1)		3,053	D	$110.4949(2)	1,081,490	I	James N. Wilson and Pamela D. Wilson Trust(5)
Common Stock	08/14/2026		S(1)		4,668	D	$111.4425(3)	1,076,822	I	James N. Wilson and Pamela D. Wilson Trust(5)
Common Stock	08/14/2026		S(1)		2,279	D	$112.6398(4)	1,074,543	I	James N. Wilson and Pamela D. Wilson Trust(5)
Common Stock								200,000	I	James N. Wilson 2025 Grantor Retained Annuity Trust
Common Stock								200,000	I	Pamela D. Wilson 2025 Grantor Retained Annuity Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.00 to $110.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.01 to $112.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.51 to $112.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for James N. Wilson	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)